O'Shaughnessy Asset Management’s Keros Therapeutics KROS Stock Holding History

O'Shaughnessy Asset Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	+126,379	New	+$1.41M	0.01%	1101

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

O'Shaughnessy Asset Management's KROS Position: Q2 2026 in Review

O'Shaughnessy Asset Management opened a new position in Keros Therapeutics (KROS) in Q2 2026: 126,379 shares worth $1.35M. The stake represents 0.01% of the portfolio and ranks #1101 among its holdings.

132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

O'Shaughnessy Asset Management held 126,379 shares of Keros Therapeutics worth $1.35M as of Q2 2026.
Keros Therapeutics was a new O'Shaughnessy Asset Management position in Q2 2026.
Keros Therapeutics made up 0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1101 holding.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.